Gene therapy of prostate xenograft tumors with a p75NTR lipoplex

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2997-3003

  Allen, Jeffrey ^a   Khwaja, Fatima ^a   Djakiew, Daniel ^a,b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Liposome; p75NTR; Prostate xenograft tumor

Indexed keywords

CELL SURFACE RECEPTOR; DNA; LIPOSOME; NEUROTROPHIN RECEPTOR; PLASMID VECTOR; PROTEIN P75; RECOMBINANT P75 NEUROTROPHIN RECEPTOR LIPOPLEX; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CELL STRAIN PC 3; CONTROLLED STUDY; ECTOPIC EXPRESSION; GENE; GENE EXPRESSION; GENE THERAPY; MOUSE; NONHUMAN; P75NTR GENE; PCMV5A PLASMID; PCMVNEO PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; RECOMBINANT PLASMID; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; LIPOSOMES; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, NERVE GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 6444229684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ferber D: Gene therapy: Safer and virus free? Science 294: 1638-1642, 2001.
2. DeSmedt SC, Demeester J and Hennink WE: Cationic polymer based gene delivery systems. Pharm Res 17: 113-126, 2000.
3. Son KK, Patel DH, Tkach D and Park A: Cationic liposome and plasmid DNA complexes formed in serum free medium under optimum transfection condition are negatively charged. Biochimica et Biophysica Acta 14466: 11-15, 2000.
4. Friedman WJ and Greene LA: Neurotrophin signaling via trks and p75. Exp Cell Res 253: 131-142, 1999.
5. Ferez M, Regan T, Pflug B, Lynch J and Djakiew D: Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 30: 274-279, 1997.
6. Ratel D and Wion D: What is, mutatis mutandis, the sequence of plasmid DNAs used in gene therapy? Med Hypothesis 60: 711-715, 2003.
7. Zhang X, Morham SG, Langenbach R and Young DA. Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451-459, 1999.
8. Rabizadeh S and Bredesen DE: Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). Cytokine Growth Factor Rev 14: 225-239, 2003.
9. Rabizadeh S, Ye X, Sperandio S, Wang JJ, Ellerby HM, Ellerby LM, Giza C, Andrusiak RL, Frankowski H, Yaron Y, Moayeri NN, Rovelli G, Evans CJ, Butcher LL, Naolan GP, Assa-Munt N and Bredesen DE: Neurotrophin dependence domain: a domain required for the mediation of apoptosis by the p75 neurotrophin receptor. J Mol Nerosci 15: 215-229, 2000.
10. NTR tumor suppressor. Mol Carcinog 36: 153-160, 2003.
11. NTR tumor suppressor induces caspase-mediated apoptosis in bladder tumor cells. Int J Cancer 105: 47-52, 2003.
12. Pflug BR, Onoda M, Lynch JH and Djakiew D: Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 52: 5403-5406, 1992.
13. NTR is a tumor suppressor in human prostate cancer. Anticancer Res 21: 3749-3756, 2001.
14. NTR suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 97: 1-7, 2002.
15. Son KK: Cationic liposome gene transfer. In: Methods in Molecular Medicine (Walther W and Stein V, eds). Totawa NJ, Human Press, Inc. 1999, pp 323-329.
16. Tomayko MM and Reynolds CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemo Pharm 24: 148-154, 1989.
17. Ajiro K, Yoda K, Utsumi K and Nishikawa Y: Alteration of cell cycle-dependent histone phoshorylation by okadaic acid. J Biol Chem 277: 13197-13201, 1996.
18. Chandee DN, Taylor WR, Hurta RA, Allis CD, Wright JA and Davie JR: Increased phosphorylation of histone H1 in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase kinase. J Biol Chem 270: 20098-20105, 1995.
19. Chao MV: The p75 neurotrophin receptor. J Neurobiol 25: 1373-1385, 1994.
20. Liepinsh E, Hag LL, Otting G and Ibanez CF: NMR structure of the death domain of the p75 neurotrophin receptor. EMBO J 16: 4999-5005 1997.
21. Shinoura N, Ohashi M, Yoshida Y, Kirino T, Asai A, Hashimoto M and Hamada H: Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas. Cancer Gene Ther 7: 224-232, 2000.
22. Tsuji H, Kawaguchi S, Wada T, Nagoya S, Inobe M, Yagita H, Okumura K, Yamashita T and Uede T: Concurrent induction of T-cell activation and apoptosis of osteocarcinoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer. Cancer Gene Ther 10: 717-725, 2003.
23. Bazzoni F and Regalia E: Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res 61: 1050-1057, 2001.
24. Gentry JJ, Casaccia-Bonnefil P and Carter BD: Nerve growth factor activation of nuclear factor kappaB through its p75 receptor is an anti-apoptotic signal in RN22 Schwannoma cells. J Biol Chem 275: 7558-7565, 2000.
25. NTR and the concept of cellular dependence: seeing how the other half die. Cell Death Differ 5: 365-371, 1998.
26. Kim SI, Kim KS, Kim HS, Kim DS, Jang Y, Chung KH and Park YS: Inhibitory effect of the salmosin gene transferred by cationic liposomes on the progression of B16BL6 tumors. Cancer Res 63: 6458-6462, 2003.
27. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L and Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62: 6712-6716, 2002.
28. Hui KM, Ang PT, Huang L and Tay SK: Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 4: 783-790, 1997.
29. Hyer ML, Sudarsham S, Schwartz DA, Hannun Y, Dong J and Norris JS: Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 10: 330-339, 2003.
30. Hetts SW: To die or not to die: an overview of apoptosis and its role in disease. JAMA 279: 300-307, 1998.
31. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-42, 1994.
32. Craciunescu CN, Brown EC, Mar MH, Albright CD, Nadeu MR and Zeisel SH: Folic acid deficiency during late gestation decreases progenitor cell proliferation and increases apoptosis in fetal mouse brain. J Nutr 134: 162-166, 2004.
33. Muskhelishvili L, Latendresse JR, Kodell RL and Henderson EB: Evolution of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) Immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem 51: 1681-1686, 2003.